Phosphorylation of dedicator of cytokinesis 1 (Dock180) at tyrosine residue Y722 by Src family kinases mediates EGFRvIII-driven glioblastoma tumorigenesis
Open Access
- 7 February 2012
- journal article
- research article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 109 (8), 3018-3023
- https://doi.org/10.1073/pnas.1121457109
Abstract
Glioblastoma, the most common primary malignant cancer of the brain, is characterized by rapid tumor growth and infiltration of tumor cells throughout the brain. These traits cause glioblastomas to be highly resistant to current therapies with a resultant poor prognosis. Although aberrant oncogenic signaling driven by signature genetic alterations, such as EGF receptor (EGFR) gene amplification and mutation, plays a major role in glioblastoma pathogenesis, the responsible downstream mechanisms remain less clear. Here, we report that EGFRvIII (also known as ΔEGFR and de2-7EGFR), a constitutively active EGFR mutant that is frequently co-overexpressed with EGFR in human glioblastoma, promotes tumorigenesis through Src family kinase (SFK)-dependent phosphorylation of Dock180, a guanine nucleotide exchange factor for Rac1. EGFRvIII induces phosphorylation of Dock180 at tyrosine residue 722 (Dock180Y722) and stimulates Rac1-signaling, glioblastoma cell survival and migration. Consistent with this being causal, siRNA knockdown of Dock180 or expression of a Dock180Y722F mutant inhibits each of these EGFRvIII-stimulated activities. The SFKs, Src, Fyn, and Lyn, induce phosphorylation of Dock180Y722 and inhibition of these SFKs by pharmacological inhibitors or shRNA depletion markedly attenuates EGFRvIII-induced phosphorylation of Dock180Y722, Rac1 activity, and glioblastoma cell migration. Finally, phosphorylated Dock180Y722 is coexpressed with EGFRvIII and phosphorylated SrcY418 in clinical specimens, and such coexpression correlates with an extremely poor survival in glioblastoma patients. These results suggest that targeting the SFK-p-Dock180Y722-Rac1 signaling pathway may offer a novel therapeutic strategy for glioblastomas with EGFRvIII overexpression.Keywords
This publication has 20 references indexed in Scilit:
- Activation of Rac1 by Src-dependent phosphorylation of Dock180Y1811 mediates PDGFRα-stimulated glioma tumorigenesis in mice and humansJCI Insight, 2011
- ELMO1 and Dock180, a Bipartite Rac1 Guanine Nucleotide Exchange Factor, Promote Human Glioma Cell InvasionCancer Research, 2007
- Coupling receptor tyrosine kinases to Rho GTPases—GEFs what's the linkCellular Signalling, 2006
- Lyn Kinase Activity Is the Predominant Cellular Src Kinase Activity in Glioblastoma Tumor CellsCancer Research, 2005
- Protein phosphatase activity of PTEN inhibited the invasion of glioma cells with epidermal growth factor receptor mutation type III expressionInternational Journal of Cancer, 2005
- Patient tumor EGFR and PDGFRA gene amplifications retained in an invasive intracranial xenograft model of glioblastoma multiformeNeuro-Oncology, 2005
- GEF means go: turning on RHO GTPases with guanine nucleotide-exchange factorsNature Reviews Molecular Cell Biology, 2005
- Rho and Rac Take Center StageCell, 2004
- Guidance of Cell Migration by the Drosophila PDGF/VEGF ReceptorCell, 2001
- A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity.Proceedings of the National Academy of Sciences, 1994